1. Home
  2. FCNCP vs CRNX Comparison

FCNCP vs CRNX Comparison

Compare FCNCP & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Citizens BancShares Inc.

FCNCP

First Citizens BancShares Inc.

HOLD

Current Price

$21.38

Market Cap

0.0

Sector

Finance

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$36.93

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FCNCP
CRNX
Founded
N/A
2008
Country
United States
United States
Employees
18141
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
3.9B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
FCNCP
CRNX
Price
$21.38
$36.93
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$76.63
AVG Volume (30 Days)
28.5K
1.1M
Earning Date
N/A
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,039,000.00
Revenue This Year
N/A
$720.10
Revenue Next Year
N/A
$184.67
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.30
$24.10
52 Week High
$22.86
$57.99

Technical Indicators

Market Signals
Indicator
FCNCP
CRNX
Relative Strength Index (RSI) 51.71 46.73
Support Level $21.40 $33.23
Resistance Level $22.06 $45.32
Average True Range (ATR) 0.28 1.68
MACD 0.01 0.50
Stochastic Oscillator 73.37 76.62

Price Performance

Historical Comparison
FCNCP
CRNX

About FCNCP First Citizens BancShares Inc.

First Citizens BancShares Inc. is a Raleigh, N.C.-based financial holding company operating through its subsidiary, First-Citizens Bank & Trust Company. It provides comprehensive retail banking, commercial lending, leasing, and wealth management services via a nationwide branch network and digital platforms. In 2023 acquisition of Silicon Valley Bank, it also specializes in banking for tech, healthcare, and innovation firms.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: